|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000143819 |
Summary for EPHX1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000143819 | Gene symbol | EPHX1 |
| Gene name | epoxide hydrolase 1 | |
| HGNC | 3401 | |
| Entrez ID | 2052 | |
| Gene type | protein_coding | |
| Synonyms | EPHX1| | |
| UniProtAcc | P07099 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for EPHX1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| EPHX1 | 3.58e+04 | -3.50e+00 | 5.30e-01 | -6.61e+00 | 3.92e-11 | 7.35e-10 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for EPHX1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for EPHX1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 6.56e-01 | 7.56e-01 | -2.38e+00 | 1.73e-02 | 3.31e-02 | -1.00e-01 |
| SARC | cg05385434 | chr1:225811168 | CGI:chr1:225809944-225810531 | promoter,gene body | 2.88e-01 | 3.88e-01 | -3.32e+00 | 9.13e-04 | 3.25e-03 | -1.00e-01 |
| CHOL | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 7.26e-01 | 6.00e-01 | 2.45e+00 | 1.42e-02 | 2.68e-02 | 1.25e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 4.32e-01 | 3.16e-01 | 2.00e+00 | 4.58e-02 | 4.65e-02 | 1.17e-01 |
| KIRP | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 7.04e-01 | 5.99e-01 | 4.09e+00 | 4.27e-05 | 1.27e-04 | 1.05e-01 |
| CHOL | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 6.00e-01 | 3.04e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.97e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 6.56e-01 | 4.84e-01 | 1.09e+01 | 1.65e-27 | 1.81e-26 | 1.72e-01 |
| LUAD | cg05385434 | chr1:225811168 | CGI:chr1:225809944-225810531 | promoter,gene body | 3.14e-01 | 2.08e-01 | 2.50e+00 | 1.23e-02 | 1.82e-02 | 1.06e-01 |
| HNSC | cg24868305 | chr1:225811028 | CGI:chr1:225809944-225810531 | promoter,gene body | 3.42e-01 | 2.05e-01 | 2.32e+00 | 2.04e-02 | 2.79e-02 | 1.36e-01 |
| HNSC | cg25152404 | chr1:225811481 | CGI:chr1:225809944-225810531 | promoter,gene body | 6.29e-01 | 4.93e-01 | 2.17e+00 | 2.99e-02 | 3.54e-02 | 1.36e-01 |
Top |
Exon skipping events with PSI in TCGA for EPHX1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for EPHX1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for EPHX1 |
| TFs related to EPHX1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| EPHX1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for EPHX1 |
| RBPs related to ES in EPHX1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | SAMD4A | exon_skip_18752 | 7.30e+00 | 9.83e-01 | 6.77e+00 | 4.47e-03 | Male-biased |
| LIHC | SRSF9 | exon_skip_18743 | 8.44e+00 | 9.84e-01 | 8.04e+00 | 9.22e-03 | Male-biased |
| LUSC | SAMD4A | exon_skip_18752 | 7.35e+00 | 9.88e-01 | 6.62e+00 | 5.30e-04 | Male-biased |
| COAD | NOVA2 | exon_skip_18764 | 9.21e+00 | 6.25e-03 | 9.59e+00 | 9.91e-01 | Female-biased |
| DLBC | NOVA2 | exon_skip_18752 | 7.75e+00 | 9.86e-01 | 7.33e+00 | 4.10e-03 | Male-biased |
| DLBC | NOVA2 | exon_skip_18764 | 9.27e+00 | 5.03e-03 | 9.67e+00 | 9.92e-01 | Female-biased |
| BRCA | SAMD4A | exon_skip_18752 | 6.45e+00 | 2.40e-03 | 7.53e+00 | 9.87e-01 | Female-biased |
| THCA | SRSF9 | exon_skip_18733 | 8.32e+00 | 9.81e-01 | 8.04e+00 | 1.16e-02 | Male-biased |
| LGG | SAMD4A | exon_skip_18752 | 6.78e+00 | 9.81e-01 | 6.37e+00 | 4.02e-03 | Male-biased |
| PAAD | SAMD4A | exon_skip_18752 | 6.80e+00 | 9.84e-01 | 6.23e+00 | 4.06e-04 | Male-biased |
| EPHX1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7527410 | chr1:220172518:C:T | - | 0.360908867672165 | 0.0185985305180367 | KIRP | Female-baised eQTL |
| rs11117693 | chr1:216842968:A:T | - | 0.12001796171791 | 0.0399267068559088 | STAD | Female-baised eQTL |
| rs17589414 | chr1:234760712:C:T | - | 0.110118776583845 | 0.0399468449910266 | STAD | Female-baised eQTL |
| rs17011319 | chr1:222087295:T:C | - | 0.115032244014933 | 1.45765326528587e-05 | KIRC | Female-baised eQTL |
| rs10495185 | chr1:222076678:T:C | - | 0.114773980197846 | 1.5458003688673e-05 | KIRC | Female-baised eQTL |
| rs2053513 | chr1:222088074:C:G | - | 0.101896999159086 | 0.000173981349478518 | KIRC | Female-baised eQTL |
| rs73118908 | chr1:222193493:A:G | - | 0.122956767676847 | 0.000313489866288723 | KIRC | Female-baised eQTL |
| rs73126941 | chr1:222211973:G:C | - | 0.122956767676847 | 0.000313489866288723 | KIRC | Female-baised eQTL |
| rs73116986 | chr1:222181468:C:T | - | 0.0951829571866337 | 0.000719441390921701 | KIRC | Female-baised eQTL |
| rs17162983 | chr1:222238605:C:T | - | 0.0896940688624978 | 0.000778429969079314 | KIRC | Female-baised eQTL |
| rs17162892 | chr1:222184050:A:T | - | 0.109877603677702 | 0.000789269778493002 | KIRC | Female-baised eQTL |
| rs11487839 | chr1:222207410:G:T | - | 0.0969169553172014 | 0.00106993634741328 | KIRC | Female-baised eQTL |
| rs76896404 | chr1:222210288:A:C | - | 0.108183457387473 | 0.00156020433460728 | KIRC | Female-baised eQTL |
| rs7514073 | chr1:215830241:C:A | - | 0.0845819295817233 | 0.00261906295330431 | KIRC | Female-baised eQTL |
| rs10797554 | chr1:234574392:T:A | - | 0.0808729993372101 | 0.00863681810594315 | KIRC | Female-baised eQTL |
| rs4520392 | chr1:215815545:A:C | - | 0.088454515677263 | 0.00919491782376687 | KIRC | Female-baised eQTL |
| rs2282029 | chr1:234565122:T:C | - | 0.087058913957625 | 0.0146434018589752 | KIRC | Female-baised eQTL |
| rs2282027 | chr1:234565438:G:A | - | 0.0868692455273119 | 0.0150492065092092 | KIRC | Female-baised eQTL |
| rs2820883 | chr1:216699119:A:C | - | -0.0684806645875361 | 0.0150708322312798 | KIRC | Female-baised eQTL |
| rs3913116 | chr1:222211387:G:T | - | 0.0746669999062888 | 0.0162093351788978 | KIRC | Female-baised eQTL |
| rs74145282 | chr1:222198404:A:C | - | 0.0741255504370886 | 0.0163097973756007 | KIRC | Female-baised eQTL |
| rs74147010 | chr1:222226285:C:A | - | 0.0737641192698906 | 0.0178166449357927 | KIRC | Female-baised eQTL |
| rs7536020 | chr1:215830215:G:A | - | 0.0792063607530567 | 0.0261212198550826 | KIRC | Female-baised eQTL |
| rs1339341 | chr1:216696109:T:C | - | -0.0621454336747872 | 0.0310502654999259 | KIRC | Female-baised eQTL |
| rs2813705 | chr1:216693634:C:T | - | -0.0619484393297354 | 0.0323653876151108 | KIRC | Female-baised eQTL |
| rs6424256 | chr1:232876154:G:A | - | 0.0856832716365073 | 0.0380720788605563 | KIRC | Female-baised eQTL |
| rs74144958 | chr1:232877053:A:G | - | 0.0856832716365073 | 0.0380720788605563 | KIRC | Female-baised eQTL |
| rs6668587 | chr1:232877310:G:A | - | 0.0856832716365073 | 0.0380720788605563 | KIRC | Female-baised eQTL |
| rs35689977 | chr1:216441004:G:A | - | 0.125358574572821 | 0.0049143628202791 | BLCA | Female-baised eQTL |
| rs12723493 | chr1:216431729:C:A | - | 0.126087456423493 | 0.00523807632114108 | BLCA | Female-baised eQTL |
| rs12038601 | chr1:216434232:A:G | - | 0.125891842206273 | 0.00538251123166266 | BLCA | Female-baised eQTL |
| rs11589613 | chr1:216435535:C:T | - | 0.125891842206273 | 0.00538251123166266 | BLCA | Female-baised eQTL |
| rs28564972 | chr1:230032085:A:G | - | 0.053272993064316 | 0.0221779367101821 | LUAD | Female-baised eQTL |
| rs2889481 | chr1:226574667:A:G | - | 0.0585764627637532 | 0.0470697044029219 | LUAD | Female-baised eQTL |
| rs12065556 | chr1:226574972:T:G | - | 0.0674843965097278 | 0.0487962180927046 | LUAD | Female-baised eQTL |
| rs76394206 | chr1:221024427:C:G | - | 0.107136840175404 | 1.02565639344191e-05 | COAD | Female-baised eQTL |
| rs76298904 | chr1:221026393:A:G | - | 0.104127275962426 | 1.99070384240323e-05 | COAD | Female-baised eQTL |
| rs7536397 | chr1:221027279:A:G | - | 0.104127275962426 | 1.99070384240323e-05 | COAD | Female-baised eQTL |
| rs7546426 | chr1:221027211:G:C | - | 0.0976845001092359 | 9.09400768771551e-05 | COAD | Female-baised eQTL |
| rs17009253 | chr1:221026746:C:T | - | 0.104504759623575 | 0.000216145280484487 | COAD | Female-baised eQTL |
| rs79371535 | chr1:221024403:C:T | - | 0.0975918504499356 | 0.000553325799073213 | COAD | Female-baised eQTL |
| rs17573664 | chr1:221025944:G:T | - | 0.094307455702318 | 0.000965880767982331 | COAD | Female-baised eQTL |
| rs77912218 | chr1:221026934:C:T | - | 0.094307455702318 | 0.000965880767982331 | COAD | Female-baised eQTL |
| rs12407402 | chr1:221018617:G:A | - | 0.059432752515978 | 0.031596317352729 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs17567651 | chr1:215882511:A:G | - | 0.184987976424127 | 0.000382086424843152 | READ | Male-baised eQTL |
| rs79627403 | chr1:234457114:C:T | - | 0.261525515135394 | 0.00270483566800158 | READ | Male-baised eQTL |
| rs11487858 | chr1:222709409:T:C | - | -0.153168948828843 | 0.00875960503681955 | READ | Male-baised eQTL |
| rs61825251 | chr1:222752033:A:G | - | -0.152776540319577 | 0.00898113043460211 | READ | Male-baised eQTL |
| rs2133186 | chr1:222621113:T:A | - | 0.146884213632418 | 0.0153096323226372 | READ | Male-baised eQTL |
| rs10915937 | chr1:223660865:C:T | - | 0.0266968023439602 | 0.0354219248924916 | KIRC | Male-baised eQTL |
| rs1319392 | chr1:222567271:C:A | - | 0.0308314936131077 | 0.0366977955552637 | KIRC | Male-baised eQTL |
| rs10915858 | chr1:223656582:G:C | - | 0.0265548520853316 | 0.0391900735017444 | KIRC | Male-baised eQTL |
| rs10910211 | chr1:233554905:C:A | - | 0.0487941404045404 | 0.0181422486397243 | LUAD | Male-baised eQTL |
| rs12144495 | chr1:228675190:T:G | - | 0.0423096356675754 | 0.0440071262931291 | LUAD | Male-baised eQTL |
| rs712070 | chr1:224526528:C:G | - | 0.0578731577517156 | 0.0095490439296023 | COAD | Male-baised eQTL |
| rs985301 | chr1:224529011:A:C | - | 0.0576443524103439 | 0.00976106968767786 | COAD | Male-baised eQTL |
| rs712073 | chr1:224529508:C:G | - | 0.0576443524103439 | 0.00976106968767786 | COAD | Male-baised eQTL |
| rs791512 | chr1:224529911:G:A | - | 0.0576443524103439 | 0.00976106968767786 | COAD | Male-baised eQTL |
| rs791511 | chr1:224529989:C:G | - | 0.0576443524103439 | 0.00976106968767786 | COAD | Male-baised eQTL |
| rs582233 | chr1:230185105:G:T | - | 0.0521557216501437 | 0.0118187589723165 | COAD | Male-baised eQTL |
| rs698277 | chr1:224534854:T:C | - | 0.0579064502483298 | 0.0124722876332222 | COAD | Male-baised eQTL |
| rs791509 | chr1:224531348:T:C | - | 0.0569284159065276 | 0.0130119546418819 | COAD | Male-baised eQTL |
| rs712082 | chr1:224538358:G:T | - | 0.0578631703292936 | 0.0193583533801346 | COAD | Male-baised eQTL |
| rs2796166 | chr1:234848836:G:C | - | -0.0693809589081757 | 0.0231796850219753 | COAD | Male-baised eQTL |
| rs1317810 | chr1:224543694:T:C | - | 0.0558135282969213 | 0.0234962670577764 | COAD | Male-baised eQTL |
| rs698280 | chr1:224545702:A:C | - | 0.0558135282969213 | 0.0234962670577764 | COAD | Male-baised eQTL |
| rs712092 | chr1:224546952:C:G | - | 0.0558135282969213 | 0.0234962670577764 | COAD | Male-baised eQTL |
| rs2794808 | chr1:224548571:A:G | - | 0.0558135282969213 | 0.0234962670577764 | COAD | Male-baised eQTL |
| rs1499283 | chr1:224549719:T:C | - | 0.0558135282969213 | 0.0234962670577764 | COAD | Male-baised eQTL |
| rs587950 | chr1:229054496:T:C | - | 0.056328234834942 | 0.0239059257097909 | COAD | Male-baised eQTL |
| rs712087 | chr1:224542789:G:A | - | 0.055037360003772 | 0.0281908139175641 | COAD | Male-baised eQTL |
| rs16847858 | chr1:224381811:G:C | - | 0.139326720158063 | 0.0283073421930434 | COAD | Male-baised eQTL |
| rs712085 | chr1:224540385:A:C | - | 0.0548763948594456 | 0.0293012204398958 | COAD | Male-baised eQTL |
| rs73123788 | chr1:224376539:G:A | - | 0.138143514370092 | 0.0397812693980017 | COAD | Male-baised eQTL |
| rs60627429 | chr1:224381060:A:C | - | 0.138143514370092 | 0.0397812693980017 | COAD | Male-baised eQTL |
| rs16847867 | chr1:224382534:A:G | - | 0.138143514370092 | 0.0397812693980017 | COAD | Male-baised eQTL |
| rs60349703 | chr1:224382716:T:C | - | 0.138143514370092 | 0.0397812693980017 | COAD | Male-baised eQTL |
| rs11809710 | chr1:224388172:C:A | - | 0.138143514370092 | 0.0397812693980017 | COAD | Male-baised eQTL |
| rs10495218 | chr1:224426431:G:A | - | 0.138143514370092 | 0.0397812693980017 | COAD | Male-baised eQTL |
| rs712068 | chr1:224525862:A:G | - | 0.0516974686486157 | 0.0400934737531566 | COAD | Male-baised eQTL |
| rs11803919 | chr1:227041254:G:A | - | 0.0938221724065554 | 0.0433888498297933 | COAD | Male-baised eQTL |
| rs7519701 | chr1:226941882:A:T | - | 0.0765079305743362 | 0.0477353021333484 | COAD | Male-baised eQTL |
| rs791510 | chr1:224531208:G:C | - | 0.0523860379955891 | 0.0478751849255605 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000143819 |
| CpG Site: cg23992403 | |
| Position to Gene: gene | |
| Male Effect: -0.471813808611093 | |
| Female Effect: - | |
 | Gene ID: ENSG00000143819 |
| CpG Site: cg26187962 | |
| Position to Gene: gene | |
| Male Effect: -0.471767781865404 | |
| Female Effect: - | |
 | Gene ID: ENSG00000143819 |
| CpG Site: cg03138928 | |
| Position to Gene: gene | |
| Male Effect: -0.287646054154846 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23992403 | chr1:225824646 | gene | -0.471813808611093 | 9.67229955722119e-29 | -0.6922274892932069 | 5.2921027236579166e-33 | LUAD |
| cg26187962 | chr1:225824252 | gene | -0.471767781865404 | 9.76559887868647e-29 | -0.6921134745730182 | 3.941037764552105e-33 | LUAD |
| cg03138928 | chr1:225817124 | gene | -0.287646054154846 | 1.33676408003731e-18 | -0.5863266132086766 | 5.514643078592587e-22 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of EPHX1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000143819 | EPHX1 | C0000771 | Abnormalities, Drug-Induced | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
| ENSG00000143819 | EPHX1 | C0007097 | Carcinoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0007114 | Malignant neoplasm of skin | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0023452 | Childhood Acute Lymphoblastic Leukemia | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0023453 | L2 Acute Lymphoblastic Leukemia | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024117 | Chronic Obstructive Airway Disease | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024121 | Lung Neoplasms | 2 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024299 | Lymphoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024302 | Reticulosarcoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024304 | Lymphoma, Mixed-Cell | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024305 | Lymphoma, Non-Hodgkin | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024306 | Lymphoma, Undifferentiated | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0026764 | Multiple Myeloma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0032914 | Pre-Eclampsia | 2 | CTD_human |
| ENSG00000143819 | EPHX1 | C0033578 | Prostatic Neoplasms | 3 | CTD_human |
| ENSG00000143819 | EPHX1 | C0034067 | Pulmonary Emphysema | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0037286 | Skin Neoplasms | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0079740 | High Grade Lymphoma (neoplasm) | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0079741 | Lymphoma, Intermediate-Grade | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0079747 | Low Grade Lymphoma (neoplasm) | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0079757 | Diffuse Mixed-Cell Lymphoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0079770 | Lymphoma, Small Noncleaved-Cell | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0205699 | Carcinomatosis | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0221227 | Centriacinar Emphysema | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0236733 | Amphetamine-Related Disorders | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0236804 | Amphetamine Addiction | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0236807 | Amphetamine Abuse | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0242379 | Malignant neoplasm of lung | 2 | CTD_human |
| ENSG00000143819 | EPHX1 | C0242488 | Acute Lung Injury | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0264393 | Panacinar Emphysema | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C0376358 | Malignant neoplasm of prostate | 3 | CTD_human |
| ENSG00000143819 | EPHX1 | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1449861 | Micronuclei, Chromosome-Defective | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1449862 | Micronuclei, Genotoxicant-Induced | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1527303 | Chronic Airflow Obstruction | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1843139 | Hypercholanemia, Familial | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C2239176 | Liver carcinoma | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C2350878 | Focal Emphysema | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C3714542 | Lymphoma, Diffuse | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| ENSG00000143819 | EPHX1 | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | CTD_human |
